Literature DB >> 31967683

Biomarkers in ovarian cancer: To be or not to be.

Rebecca Arend1, Alba Martinez1, Tomasz Szul1, Michael J Birrer1.   

Abstract

Biomarkers are becoming increasingly important in the treatment of epithelial ovarian cancer. Recent work from many laboratories has begun to provide clinically meaningful biomarkers. This review summarizes the state of the science regarding biomarkers for stratifying early-stage patients into those who benefit from adjuvant treatment, primary debulking versus interval debulking, and specific targeted therapy. In addition, new molecular imaging technologies have been developed to allow the surgeon to resect subvisible tumor deposits. These efforts should increase clinical effectiveness while minimizing toxicities for patients.
© 2019 American Cancer Society.

Entities:  

Keywords:  biomarkers; genomics; molecular signatures; ovarian cancer; targeted therapy

Mesh：

Substances：

Year:  2019        PMID： 31967683     DOI： 10.1002/cncr.32595

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  14 in total

1.  The Expression and Role Analysis of Methylation-Regulated Differentially Expressed Gene UBE2C in Pan-Cancer, Especially for HGSOC.

Authors:  Jiajia Li; Yating Sun; Xiuling Zhi; Qin Li; Liangqing Yao; Mo Chen
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

2.  Clinical significance for combined coagulation indexes in epithelial ovarian cancer prognosis.

Authors:  Jiani Yang; Yue Jin; Shanshan Cheng; Chao Wang; Nan Zhang; Shan Huang; Yaqian Zhao; Yu Wang
Journal:  J Ovarian Res       Date:  2021-08-17       Impact factor: 4.234

3.  Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites.

Authors:  Judith E den Ouden; Guido J R Zaman; Jelle Dylus; Antoon M van Doornmalen; Winfried R Mulder; Yvonne Grobben; Wilhelmina E van Riel; Joanne A de Hullu; Rogier C Buijsman; Anne M van Altena
Journal:  Oncotarget       Date:  2020-12-08

4.  HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells.

Authors:  Ahlam Ali; Fengyu Zhang; Aaron Maguire; Tara Byrne; Karolina Weiner-Gorzel; Stephen Bridgett; Sharon O'Toole; John O'Leary; Caitlin Beggan; Patricia Fitzpatrick; Amanda McCann; Fiona Furlong
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

5.  Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.

Authors:  Li Ning; Jinghe Lang; Lingying Wu
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

6.  Clinical significance of microRNA-125b and its contribution to ovarian carcinogenesis.

Authors:  Ya-Nan Bi; Jin-Ping Guan; Liming Wang; Ping Li; Feng-Xia Yang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

Review 7.  Radiomics and radiogenomics in ovarian cancer: a literature review.

Authors:  S Nougaret; Cathal McCague; Hichem Tibermacine; Hebert Alberto Vargas; Stefania Rizzo; E Sala
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

Review 8.  Role of Mitochondria in Interplay between NGF/TRKA, miR-145 and Possible Therapeutic Strategies for Epithelial Ovarian Cancer.

Authors:  Daniela B Vera; Allison N Fredes; Maritza P Garrido; Carmen Romero
Journal:  Life (Basel)       Date:  2021-12-21

9.  NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells.

Authors:  Wen-Jing Liu; Ying-Xue Huang; Wei Wang; Ye Zhang; Bing-Jie Liu; Jian-Ge Qiu; Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

10.  Elevated LINC00909 Promotes Tumor Progression of Ovarian Cancer via Regulating the miR-23b-3p/MRC2 Axis.

Authors:  Xu Yang; Guixia Wu; Fan Yang; Lang He; Xiaohui Xie; Lan Li; Lei Yang; Yulan Ma; Qin Zhang; Jiao Chen; SiYing Zou; Qian Han; Yan Wang; Shuai Liu; Juan Li; Bin Han; KaiJiang Liu
Journal:  Oxid Med Cell Longev       Date:  2021-07-21       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.